Switch theme
Sign up to access all valuation multiples
RTW Biotech Opportunities Ltd is an investment fund focused on identifying transformative assets with growth potential across the life sciences sector. Its approach is driven by applying deep scientific expertise with a long-term investment horizon. Geographically, it operates in U.S. &Canada, UK & EU, and Rest of the world.
2017
n/a
LTM Revenue n/a
LTM EBITDA n/a
$383M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
RTW Biotech Opportunities has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, RTW Biotech Opportunities achieved revenue of $38.7M and an EBITDA of n/a.
RTW Biotech Opportunities expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RTW Biotech Opportunities valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $86.3M | $38.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | n/a | n/a | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$39.4M | $83.2M | XXX | XXX | XXX |
| Net Margin | -46% | 215% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, RTW Biotech Opportunities's stock price is $1.
RTW Biotech Opportunities has current market cap of $383M, and EV of $383M.
See RTW Biotech Opportunities trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $383M | $383M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, RTW Biotech Opportunities has market cap of $383M and EV of $383M.
RTW Biotech Opportunities's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate RTW Biotech Opportunities's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for RTW Biotech Opportunities and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $383M | XXX | XXX | XXX |
| EV/Revenue | 9.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | 11.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRTW Biotech Opportunities's NTM/LTM revenue growth is n/a
RTW Biotech Opportunities's revenue per employee for the last fiscal year averaged $InfinityT, while opex per employee averaged $InfinityT for the same period.
Over next 12 months, RTW Biotech Opportunities's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate RTW Biotech Opportunities's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for RTW Biotech Opportunities and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -55% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $InfinityT | XXX | XXX | XXX | XXX |
| Opex per Employee | $InfinityT | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 12% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| XXX | XXX | XXX | XXX | XXX | XXX | |
| Waha Capital | XXX | XXX | XXX | XXX | XXX | XXX |
| CVC Capital Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| EXOR | XXX | XXX | XXX | XXX | XXX | XXX |
| Pengana Private Equity | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RTW Biotech Opportunities acquired XXX companies to date.
Last acquisition by RTW Biotech Opportunities was XXXXXXXX, XXXXX XXXXX XXXXXX . RTW Biotech Opportunities acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was RTW Biotech Opportunities founded? | RTW Biotech Opportunities was founded in 2017. |
| Where is RTW Biotech Opportunities headquartered? | RTW Biotech Opportunities is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| Is RTW Biotech Opportunities publicy listed? | Yes, RTW Biotech Opportunities is a public company listed on LON. |
| What is the stock symbol of RTW Biotech Opportunities? | RTW Biotech Opportunities trades under RTW ticker. |
| Who are competitors of RTW Biotech Opportunities? | Similar companies to RTW Biotech Opportunities include e.g. , Waha Capital, CVC Capital Partners, EXOR. |
| What is the current market cap of RTW Biotech Opportunities? | RTW Biotech Opportunities's current market cap is $383M |
| What is the current revenue growth of RTW Biotech Opportunities? | RTW Biotech Opportunities revenue growth between 2023 and 2024 was -55%. |
| Is RTW Biotech Opportunities profitable? | Yes, RTW Biotech Opportunities is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
